A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Active:	Yes
Cancer Type:	Melanoma	NCT ID:	NCT06246916
Trial Phases:	Phase III	Protocol IDs:	R3767-ONC-22122 (primary) NCI-2024-04722
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Regeneron Pharmaceuticals, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06246916

Summary

This study is researching an experimental drug called fianlimab (also known as REGN3767),
combined with another medication called cemiplimab (also known as REGN2810), called
"study drugs". The study is focused on patients with a type of skin cancer known as
melanoma. The aim of the study is to see how safe and effective the combination of
fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of
two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™
and approved for the treatment of melanoma in adults and children.

The study is looking at several other research questions, including:

- What side effects may happen from taking the study drugs.

- How much study drug is in the blood at different times.

- Whether the body makes antibodies against the study drugs (which could make the drug
less effective or could lead to side effects)

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.